Unilife Medical Solutions LTD: PINK (UNIFF)

Research Home

SmallCapTube.com

Client Links

Search Waterville

Distribution Partners

Tear Sheets

Unilife Medical Solutions Ltd. (PINK:UNIFF) develops and supplies innovative safety medical devices to healthcare and pharmaceutical markets. Unilife is targeting pharmaceutical markets for ready to fill (prefilled) safety syringes as well as healthcare markets that mandate the use of sharps safety devices to prevent needlestick injuries. The Company has developed a patent-protected portfolio of safety syringes, with product lines including Unifill™ (formerly referred to as the Unilife Ready-to-Fill Syringe), Unitract™ 1mL Insulin and Safe Syringes, Unitract™ Clinical Range, and a new prefilled syringe, Unifill™ Select, for which the Company filed US Patent applications in late 2009. The key distinctive feature in all of Unilife’s safety syringes is that the operator may control the speed of automatic needle retraction within a fully integrated safety syringe. This novel combination of safety features, which Unilife does not believe is available with any other technology on the market today, can virtually eliminate the risk of acquiring bloodborne infections, such as the human immunodeficiency virus (HIV) or hepatitis C, via needlestick injuries or aerosol (blood splatter). In July 2008, sanofi-aventis SA (SNY-NYSE)—the world’s fourth largest pharmaceutical group and largest purchaser of prefilled syringes—signed an Exclusive Agreement with Unilife, in which sanofi-aventis paid US$13.9 million (€10 million) for the right to negotiate the purchase of the Unifill™ Syringe for five years. Sanofi-aventis is also financing Unilife’s industrialization program for Unifill™, which could total up to US$23.6 million (€17 million). Unilife believes this alliance validates its technology and competency in developing and operating automated assembly systems.

Unilife Report by ProActive

Copyright © 2002 - 2010 Waterville Investment Research. All rights Reserved.Waterville Investment Research, and affiliates (WR), publishes reports providing information on selected companies. WR is not a registered investment advisor or broker-dealer. These reports are provided as an information service only, and the statements and opinions in these reports should not be construed as an offer or solicitation to buy or sell any security. WR accepts no liability for any loss arising from an investor's reliance on or use of these reports. An investment in any company is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. WR or an affiliate of WR has been/will be or may be compensated in Rule 144 stock of the Company for the publication and circulation of these reports. The maximum amount charged by WR is $75,000 in Rule 144 stock per report. WR intends to sell all or a portion of the of the Rule 144 stock in accordance with all securities laws, which prevents WR from selling stock for a period of six months to one year depending on the Bulletin Board and Pink Sheets regulations. WR, as a matter of internal policy, will not buy or sell shares of Company(s) stock in the open market. These reports contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. For further details concerning these risks and uncertainties, see the SEC filings of the individual Companies including the company's most recent annual and quarterly reports.